Side effects of Effient may be linked to an increased relative risk of cancer, according to recent research. Some experts have called for a “black box” warning to be added to Effient, alerting patients that the medication may cause cancer or growth of solid tumors.
EFFIENT LAWSUIT STATUS: The potential for future lawsuits on behalf of individuals diagnosed with cancer after using the blood thinner are being reviewed by Effient lawyers.
MANUFACTURER: Eli Lilly.
OVERVIEW: Effient (prasugrel) is a new blood-thinner approved by the FDA in 2009 for the prevention of blood clots in people who have received angioplasty for clogged blood vessels.
Effient works by preventing blood platelets from sticking together, which some experts have speculated may inhibit the body’s natural defenses against tumors.
Following publication of a study in June 2010 in the Archives of Internal Medicine, which found that patients given Effient may be 60% more likely to develop certain solid-tumor cancers than those given Plavix, experts have called for new warnings and for doctors to limit prescriptions of Effient until more data is available, recommending that use be limited to a duration of weeks instead of months.
EFFIENT CANCER SIDE EFFECTS: According to data reviewed from clinical trials, which included 13,608 people, patients who take Effient had a higher rate of solid tumors, excluding some skin cancers and brain tumors, than those who received Plavix. The rate was 1.4% with Effient users compared to 0.9% of Plavix users.
Although Eli Lilly has maintained that it is unlikely that Effient side effects increase the risk of cancer, some experts have called for the FDA to add a “black box warning” and indicated that additional studies are necessary before the risk of cancer from Effient can be ruled out.
The potential for Effient cancer lawsuits are being reviewed by lawyers as a result of Eli Lilly’s possible failure to adequately research the side effects of Effient and warn about the potential risks associated with use of the medication.